Dr. Tanya Gottlieb serves as Vice President of Scientific Affairs at MeMed, a company pioneering host response technologies. She joined in 2014 and leads MeMed’s international collaborations and non-dilutive funding projects, focused on improving patient management and antibiotic stewardship via tools that support decision making on appropriate use. Before joining MeMed, Dr. Gottlieb was Director of Business Development at BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV), an innovative start-up developing a universal flu vaccine, where she established relationships with the National Institute of Health (US) and European Commission. Dr. Gottlieb conducted her postdoctoral research at the Weizmann Institute of Science, Israel and the Fred Hutchinson Cancer Research Center in Seattle, WA, USA. She holds a BA in Natural Sciences and a PhD from Cambridge University in the UK and an MBA from the Technion in Israel.